TLDR
- ImmunityBio stock rallied 30.79% Thursday to close at $3.95 after announcing Anktiva sales grew 700% in 2025
- Full-year revenue hit $113 million compared to $15 million in 2024, with Q4 revenue reaching $38.3 million
- The company received Saudi FDA approval for Anktiva in lung cancer, the first global approval for this indication
- Anktiva also gained Saudi approval for bladder cancer, joining existing U.S., U.K., and conditional EU approvals
- Three analysts rate the stock a Strong Buy with an average target price of $7.33, implying 85.57% upside
ImmunityBio delivered a standout performance Thursday with shares climbing 30.79% to $3.95. The biotech company’s preliminary 2025 results showed Anktiva revenue skyrocketed from $15 million to $113 million year-over-year.
Volume surged to 70.4 million shares, approximately 442% higher than the three-month average of 13 million. The stock has gained momentum this week following multiple catalysts.
The company reported Q4 2025 revenue of $38.3 million, marking a 20% increase from the prior quarter. Year-over-year, fourth quarter sales jumped 431% from the same period in 2024.
Regulatory Wins Fuel Growth Story
Saudi FDA approved Anktiva in combination with checkpoint inhibitors for metastatic non-small cell lung cancer. This approval marks a first for the therapy globally in this indication.
The Saudi regulatory authority also greenlit Anktiva plus BCG for BCG-unresponsive bladder cancer. The company now maintains approvals across multiple regions including the U.S., U.K., and conditional EU approval.
ImmunityBio released positive lung cancer data earlier in the week. These clinical results strengthen the case for broader adoption across different cancer types.
Unit sales of Anktiva increased 750% during 2025 versus 2024. The IL-15-based therapy works by activating T cells and natural killer cells to fight cancer.
Clinical Pipeline Advances
The company’s Phase 2b trial for first-line, BCG-naïve bladder cancer is running ahead of schedule. Full enrollment is projected for the first half of 2026.
Anktiva has demonstrated strong response rates in bladder cancer patients. The treatment provides long-lasting benefits for those with BCG-unresponsive disease.
ImmunityBio’s gross margin reached 80.41% as product sales scaled throughout the year. The company’s market capitalization now stands at $3.9 billion.
Wall Street maintains a Strong Buy consensus based on three Buy ratings issued in the past three months. The average analyst price target of $7.33 suggests 85.57% upside from current levels.
The stock’s 52-week trading range spans $1.83 to $4.27. ImmunityBio has fallen 89% since going public in 2015.
Broader market indices posted modest gains Thursday. The S&P 500 advanced 0.27% while the Nasdaq Composite rose 0.25%.
Biotech competitors moved lower during the session. Incyte closed down 0.67% at $105.24, while Vertex Pharmaceuticals declined 2.36% to $438.92.
The 20% sequential revenue growth from Q3 to Q4 demonstrates building commercial momentum. Physician adoption appears to be accelerating as more treatment centers gain experience with the therapy.
International expansion through Saudi Arabia could open doors to additional markets. The regulatory approvals provide validation for Anktiva’s efficacy across different cancer types.
The Phase 2b trial advancement positions ImmunityBio for potential label expansion next year. Completion ahead of schedule could accelerate the path to broader market access.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
